Implementation of a chip-based MDTMA platform for evaluating prostate cancer treatment response and mode of action.
Prostate cancer will affect 1 in 7 Canadian males. While the number of therapeutic options is increasing, matching each patient to the right therapy remains as the challenge for a personalized approach to patient management. Currently, most of the attention has focused on identifying biological tags that can predict patients response. We have developed an alternative approach that can keep tumor samples alive outside the body to test therapeutic agents directly on the tumor. We believe that this approach addresses the challenges in patient management by developing a method to test tumor biopsy material in a miniaturized channel device that traps the tissue and allows us to test specific therapeutic agent. The first goal of the present study is to verify whether a tumor maintained in the miniaturized system responds to hormonal and chemotherapeutic therapies in the same way as when the same tumor is treated in the patient body. TO BE CONT'D